Alerts will be sent to your verified email
Verify EmailSHIVALIK
|
Shivalik Rasayan
|
Albert David
|
Medicamen Biotech
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Chemicals
|
|||
|
Capacity Utilization - Dimethoate
|
95.0 % | n/a | n/a |
|
Realization/Tonne - Dimethoate
|
299080.92 Rs/MT | n/a | n/a |
|
Realization/Tonne - Sodium hydrosulfide
|
4487.46 Rs/MT | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
6.54 % | 11.47 % | 6.92 % |
|
5yr average Equity Multiplier
|
1.82 | 1.63 | 1.44 |
|
5yr Average Asset Turnover Ratio
|
0.44 | 0.62 | 0.55 |
|
5yr Avg Net Profit Margin
|
7.94 % | 11.31 % | 8.69 % |
|
Price to Book
|
0.69 | 1.04 | 1.37 |
|
P/E
|
35.22 | 0.0 | 39.88 |
|
5yr Avg Cash Conversion Cycle
|
100.7 Days | -77.77 Days | 49.75 Days |
|
Inventory Days
|
80.64 Days | 47.91 Days | 84.58 Days |
|
Days Receivable
|
107.04 Days | 27.87 Days | 139.4 Days |
|
Days Payable
|
166.18 Days | 140.35 Days | 264.75 Days |
|
5yr Average Interest Coverage Ratio
|
8.55 | 93.73 | 7.03 |
|
5yr Avg ROCE
|
8.54 % | 14.69 % | 10.34 % |
|
5yr Avg Operating Profit Margin
|
17.6 % | 9.55 % | 15.51 % |
|
5 yr average Debt to Equity
|
0.2 | 0.02 | 0.15 |
|
5yr CAGR Net Profit
|
-1.04 % | -4.92 % | -11.57 % |
|
5yr Average Return on Assets
|
3.57 % | 7.03 % | 4.73 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
47.37 % | 62.24 % | 40.46 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-2.95 % | 0.2 % | -2.75 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Shivalik Rasayan
|
Albert David
|
Medicamen Biotech
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|